The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC)

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 4, 2013, Pages 407-413

  Audenet, François ^a   Yates, David R ^c   Cussenot, Olivier ^b   Rouprêt, Morgan ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre de Recherche sur les Pathologies Prostatiques   (France)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Chemotherapy; Prognosis; Recurrence; Renal pelvis; Ureter; Urinary tract cancer; Urothelial carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; TELOMERASE; VINBLASTINE; VINFLUNINE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; MICROSATELLITE INSTABILITY; NEPHROURETERECTOMY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; TRANSITIONAL CELL CARCINOMA; UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; PROGNOSIS; UROLOGIC NEOPLASMS;

EID: 84876743074     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.07.016     Document Type: Review

References (35)

1. Hall M.C., Womack S., Sagalowsky A.I., et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients. Urology 1998, 52:594-601.
2. Margulis V., Shariat S.F., Matin S.F., et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009, 115:1224-1233.
3. Cornu J.N., Roupret M., Carpentier X., et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010, 28:151-156.
4. Roupret M., Traxer O., Tligui M., et al. Upper urinary tract transitional cell carcinoma: Recurrence rate after percutaneous endoscopic resection. Eur Urol 2007, 51:709-714.
5. McNeill S.A., Chrisofos M., Tolley D.A. The long-term outcome after laparoscopic nephroureterectomy: A comparison with open nephroureterectomy. BJU Int 2000, 86:619-623.
6. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987, 60:574-585.
7. Genega E.M., Porter C.R. Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review. Am J Clin Pathol 2002, 117(Suppl):S36-S48.
8. Catto J.W., Yates D.R., Rehman I., et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol 2007, 177:1715-1720.
9. Miyake H., Hara I., Gohji K., et al. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol 1998, 82:494-498.
10. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
11. Olgac S., Mazumdar M., Dalbagni G., et al. Urothelial carcinoma of the renal pelvis: A clinicopathologic study of 130 cases. Am J Surg Pathol 2004, 28:1545-1552.
12. Park S., Hong B., Kim C.S., et al. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004, 171:621-625.
13. Amira N., Rivet J., Soliman H., et al. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol 2003, 170:1151-1154.
14. Oosterlinck W., Solsona E., van der Meijden A.P., et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol 2004, 46:147-154.
15. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
16. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999, 17:3173-3181.
17. Ozsahin M., Zouhair A., Villa S., et al. Prognostic factors in urothelial renal pelvis and ureter tumors: A multicenter Rare Cancer Network study. Eur J Cancer 1999, 35:738-743.
18. Bellmunt J, Sylvester R, Bekka N, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. EORTC 30987. Intergroup Study. Proceedings of the ASCO Congress 2007, Chicago, June 2007. [Abstract 5030].
19. Bamias A., Moulopoulos L.A., Koutras A., et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006, 106:297-303.
20. Vaughn D.J., Srinivas S., Stadler W.M., et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 2009, 115:4110-4117.
21. Stenzl A., Cowan N.C., De Santis M., et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 55:815-825.
22. O'Donnell P.H., Stadler W.M. The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol 2009, Epub ahead of print.
23. Igawa M., Urakami S., Shiina H., et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 1995, 55:74-77.
24. Kwak C., Lee S.E., Jeong I.G., et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006, 68:53-57.
25. Lee S.E., Byun S.S., Park Y.H., et al. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 2006, 77:22-26.
26. Michael M., Tannock I.F., Czaykowski P.M., et al. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: The Princess Margaret Hospital experience. Br J Urol 1998, 82:366-372.
27. Soga N., Arima K., Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 2008, 15:800-803.
28. Hellenthal N.J., Shariat S.F., Margulis V., et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009, 182:900-906.
29. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205. Collaboration ABCAM-a, Discussion 205-6.
30. Kikuchi E., Margulis V., Karakiewicz P.I., et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 2009, 27:612-618.
31. Inman B.A., Tran V.T., Fradet Y., et al. Carcinoma of the upper urinary tract: Predictors of survival and competing causes of mortality. Cancer 2009, 115:2853-2862.
32. Roupret M., Fromont G., Azzouzi A.R., et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005, 65:1233-1237.
33. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
34. Bertagnolli M.M., Niedzwiecki D., Compton C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009, 27:1814-1821.
35. Eltz S., Comperat E., Cussenot O., et al. Molecular and histologic markers in urothelial carcinomas of the upper urinary tract. BJU Int 2008, 102:532-535.